T he pathogenesis of inflammatory bowel diseases (IBDs) such as Crohn's disease (CD) and ulcerative colitis (UC) remains poorly understood. However, a crucial role of the immune system in the initiation and perpetuation of chronic intestinal inflammation is beyond question. [1] [2] [3] Lymphocyte homing from postcapillary high endothelial venules to the inflamed gut contributes to amplification of intestinal effector T lymphocyte (T effector [Teff] ) populations that outnumber increased regulatory T cells (Tregs). 4 Subsequently, augmented cytokine signaling in effector T cells leads to further immune cell activation, resulting in damage of intestinal structures and clinical symptoms like diarrhea, bleeding, or pain. 5 Homing to the inflamed intestine is a tightly regulated multistep process that has only been rudimentarily uncovered. In general, lymphocytes establish contact with and roll along the endothelium through interaction of selectins with selectin ligands. This is followed by chemokine-induced cell activation and promotion of firm adhesion to the endothelium by binding of integrins to respective addressins. Subsequently, lymphocytes may cross the endothelial wall by migrating paracellularly or transcellularly to the lamina propria. 6 In the intestine, interaction of a4b7 integrin with mucosal vascular addressin cell adhesion molecule (MAdCAM)-1 is an important and gut-specific homing mechanism. 7 Consequently, therapeutic blockade of a4b7 by the monoclonal antibody vedolizumab that was developed from the mouse antihuman a4b7 antibody Act-1 8 is successfully used for clinical treatment of patients with both UC and CD. 9, 10 In addition, adhesion of a4b1 to vascular cell adhesion molecule (VCAM)-1 has been identified as an important mechanism for gut homing of lymphocytes, but successful therapeutic inhibition with the anti-a4 antibody natalizumab 11 was restricted because of severe cerebral viral infections probably resulting from concurrent blockade of lymphocyte homing to the central nervous system. 12 We have recently shown that vedolizumab decreases colonic homing of UC Teffs in a humanized mouse model in vivo, and that CD Teff cells express a4b7 similarly to UC Teff cells. 13 However, the functional implications for in vivo homing of Teff cells from patients with CD have not yet been addressed. Moreover, clinical data suggest that vedolizumab might be more beneficial in patients with UC than in those with CD, 14 but a molecular explanation is missing.
In this study, we demonstrate that inhibition of a4b7-dependent homing of Teff cells from CD may be bypassed by compensatory homing to the ileum through a4b1 integrin in a humanized mouse model in vivo. Our data indicate that due to an essential role of the a4b1 integrin/VCAM-1 pathway for gut homing in CD, therapeutic interference with a4b7 integrin might not work as well in this disease.
MATERIALS AND METHODS

Patients with IBD
After obtaining informed written consent, peripheral blood and gut samples from patients with CD (n ¼ 116) and UC (n ¼ 39) were collected according to the regulations of the local Ethics Committee at the Medical Clinic I of the University Hospital Erlangen. Controls (n ¼ 49) came from blood and tissue specimens provided by healthy donors and tumor patients, respectively. IBD gut samples were from areas of active disease. Patients receiving vedolizumab were recruited during the induction phase of treatment and followed up for 14 6 0.5 weeks with periodic collection of blood samples.
Immunohistochemistry
Cryopreserved tissue sections were fixed in 4% paraformaldehyde and sequentially blocked with avidin/biotin blocking reagent (Vector Laboratories, Burlingam, CA) and proteinblocking reagent (Roth, Karlsruhe, Germany). Primary antibodies specific for CD4 (RPA-T4; BD, Franklin Lakes, NJ), a4 integrin (D2E1; Cell Signaling, Danvers, MA), b1 integrin (JB1B; Abcam, Cambridge, UK), a4b7 integrin (Vedolizumab; Takeda, Osaka, Japan), a4 integrin (Natalizumab; Biogen, Cambridge, MA), and CCR2 (polyclonal; Abcam) were used. The slides were subsequently incubated with fluorescent-or biotin-labeled secondary antibodies (Vectorlabs and Merck, Darmstadt, Germany) followed by treatment with Dylight 488-or Cy3-conjugated streptavidin (BioLegend, San Diego, CA), if applicable. Natalizumab was directly labeled with Alexa Fluor 647 (Thermo Fisher, Waltham, MA). Nuclei were counterstained with Hoechst reagent (Molecular Probes, Eugene, OR), and samples were analyzed by fluorescence and confocal microscopy (DMI6000B and LSM SP8; Leica, Wetzlar, Germany). Single and double positive cells in at least 3 high power fields were counted.
Cell Isolation and In Vitro Treatment
Peripheral blood mononuclear cells were isolated by density gradient centrifugation with Pancoll (Pan Biotech, Aidenbach, Germany). CD4 + CD25 2 Teff cells were isolated using the CD4 + CD25 + Treg isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturer's instruction. Where indicated, cells were cultured in RPMI 1640 medium (Thermo Fisher) with 10% FCS (Pan Biotech) and 1% penicillin/streptomycin (Biochrom, Berlin, Germany) and treated with vedolizumab (Takeda) and natalizumab (Biogen) at the indicated concentrations.
Flow Cytometry
For flow cytometric analyses, human cells were incubated with antibodies against CD4 (VioBlue, VIT4; Miltenyi Biotec), CCR2 (BV605, K036C2; Biolegend), a4-integrin (FITC, MZ18-24A9; Miltenyi Biotec), b7-integrin (PerCP/Cy5.5, FIB27; Biolegend), ß1-integrin (AF647, TS2/16; Biolegend), or FoxP3 (PE, 236A/E7, eBioscience, San Diego, CA). For intracellular staining, cells were treated with the Foxp3/Transcription Factor Staining Buffer Set (eBioscience). Analyses were performed on an LSR Fortessa instrument (BD).
MAdCAM-1/VCAM-1 Adhesion Assay
Adhesion assays were performed on epoxy-coated glass slides (Neolab, Heidelberg, Germany) as previously described. 13, 15 Wells were coated with Fc chimera of rhMAdCAM-1 and rhVCAM-1 (both 5 mg/mL, both from R&D, Minneapolis, MN) in 150 mM NaCl with 20 mM HEPES (AMRESCO, Solon, OH) at 378C overnight followed by blocking with 5% BSA at 378C for 2 hours. Two hundred thousand cells (purified CD4 + or CD4 + CD25 2 cells as indicated) in adhesion buffer were added for 90 minutes at 378C. After washing, adherent cells were counterstained with Hoechst, and slides were analyzed by fluorescence and confocal microscopy. In blocking experiments, cells were treated with the indicated concentrations of vedolizumab and natalizumab or 100 nM or the small molecule a4b1 inhibitor BIO5192 (Tocris Bioscience, Bristol, UK).
Dynamic VCAM-1 Adhesion Assay
Ultra-thin glass capillaries (Vitrocom, Mountain Lakes, NJ) were coated with Fc chimera of rhVCAM-1 (5 mg/mL) and subsequently blocked with 5% BSA, for 1 hour at 378C each. Cells were labeled with carboxyfluorescein succinimidyl ester (CFSE) (Life Technologies, Carlsbad, CA) and treated as mentioned above. The glass capillaries were connected with plastic tubings, and suspensions of 1.5 million cells/mL were perfused through the capillaries at a rate of 2.0 mL/h by a perfusion pump (B. Braun, Melsungen, Germany). Analyses were performed by taking clips of 3 minutes length with time-lapse confocal microscopy. For quantification, 3 sequential images at the beginning and the end of these clips were exported, colored in red, green, and blue, and subsequently merged in ImageJ. In the composite image, stationary cells appeared white, whereas moving cells kept the assigned color. White cells at the beginning and the end of the sequences were counted, and the difference (i.e., number of newly adhering cells within 3 minutes) was calculated.
Humanized Mouse Model of In Vivo Homing to the Inflamed Gut NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) and RAG1-deficient (B6 RAG1 2/2 ) mice lacking native lymphoncytes were housed in individually-ventilated cages. Dextran sodium sulfate (DSS) colitis and adoptive transfer experiments were performed as recently described. 13 Briefly, 2 million Teff cells were labeled with CFSE and treated with 100 mg/mL vedolizumab or 100 mg/mL natalizumab overnight, where specified. Where indicated, mice were injected with 0.5 mg of the a4b1 inhibitor BIO5192 12 hours before adoptive transfer of cells. Mice were anesthetized with ketamine/xylazine by intraperitoneal injection. Subsequently, Hoechst dye was injected into the tail vein for murine cell staining. CFSE-labeled cells and Texas Red Dextran (Life technologies) for vessel staining were injected into the ileocolic artery guided by a stereomicroscope (Leica). For in vivo imaging, the colon was longitudinally opened, and the mucosa positioned on a glass transparent petri dish before intravital analysis with an SP8 confocal microscope (Leica).
For flow cytometric analyses, mice were killed 1 hour after adoptive transfer, and T cell-enriched lamina propria mononuclear cells were isolated using the lamina propria isolation kit (Miltenyi Biotec). The CFSE + fraction was quantified by flow cytometry.
Statistics
Statistical differences were identified using analysis of variance or Student's t test where applicable in Graph Pad Prism (Graph Pad Software). Levels of significance are indicated by asterisks (*P , 0.05, **P , 0.01, ***P , 0.001). Graphs display mean values with SEM indicated by error bars.
Ethical Considerations
Patient material was obtained after informed written consent and according to the regulations and approval of the Ethics Committee of the University Erlangen-Nuremberg. Mice were housed and cared for according to the Guidelines for the Care and Use of Laboratory Animals, and experiments were performed according to the approval of the Government of Lower Franconia.
RESULTS
Vedolizumab Blocks Adhesion of CD Teff Cells to MAdCAM-1 In Vitro but Does Not Reduce CD Teff Cell Homing to the Inflamed Colon In Vivo
Recent data from our group have shown that binding of Teff cells from patients with UC to MAdCAM-1 is blocked by vedolizumab in vitro, and that vedolizumab treatment results in reduced in vivo Teff homing to the inflamed gut in a humanized mouse model. 13 However, the question of whether similar observations can be made in Teff cells from patients with CD remained unclear. We therefore set out to explore these interactions in CD. As expected, vedolizumab inhibited in vitro adhesion of overall blood CD4 + T cells and CD4 + CD25 2 Teff cells from patients with CD and controls to MAdCAM-1-coated glass slides, although effects in CD were not clearly dose-dependent (Fig. 1A , Supplemental Digital Content 1A, http://links.lww.com/IBD/B455). Next, we investigated a4b7 inhibition of CD Teff cells by vedolizumab in the aforementioned humanized mouse model, in which human T cells are injected into the ileocolic artery of immunodeficient colitic mice. Colitis was induced with DSS before injection of CFSE-labeled CD Teff cells and fluorescence dyes as described in the methods section.
By means of intravital confocal microscopy, human CD lymphocytes that had homed to the colonic lamina propria could be observed. Unexpectedly, and in contrast to our previous observations in UC, 13 however, no significant difference between untreated and vedolizumab-treated CD Teff cells was noticed microscopically or in flow cytometric analysis of CFSE + human cells within the lamina propria mononuclear cells from the murine colon (Fig. 1B) .
This was mirrored by the finding that unlike in UC, 13 the ratio of effector CD4 + Foxp3 2 and regulatory CD4 + Foxp3 + T cells in the peripheral blood of patients with CD receiving vedolizumab did not change over the course of therapy (Supplemental Digital Content 1B, http://links.lww.com/IBD/B455). Taken together, these data suggested that despite efficient blockade of a4b7-mediated Teff cell adhesion to MAdCAM-1, and although CD and UC Teffs express similar levels of a4b7, 13 homing through a4b7 might be less functionally relevant for colonic in vivo homing of CD Teff cells to the inflamed gut in our humanized mouse model compared with UC Teff cells.
Increased Expression of a4b1 on Peripheral and Intestinal Teff Cells from Patients with CD and Reciprocal Regulation of Peripheral and Intestinal a4b1 Expression Under Vedolizumab Therapy
We reasoned that this finding could be due to a preferential or compensatory use of alternative homing pathways by CD Teff cells. Accordingly, we analyzed the expression of various alternative homing markers on Teff cells in the peripheral blood of patients with CD. Although we detected no differences in the expression of several homing markers like CD62L or PSGL-1 (Supplemental Digital Content 2A, http://links.lww.com/IBD/ B456), we found that the number of a4 + b1 high Teff cells was significantly increased in CD compared with UC and controls. Similarly, more peripheral CCR2 + Teff cells were found in CD as compared to control patients ( Fig. 2A) .
We therefore further addressed these markers and assessed their intestinal expression by immunohistochemistry. Matching with higher expression in the peripheral blood, the number of a4 + b1 + and CD4 + CCR2 + cells was significantly higher in cryosections from inflamed CD compared with inflamed UC and control patients (Fig. 2B , Supplemental Digital Content 2B, http://links.lww.com/IBD/B456).
To explore whether these molecules might be a potential bypass of a4b7-dependent homing, we measured the expression of a4b1 and CCR2 in patients with CD receiving clinical vedolizumab therapy. Although CCR2 levels did not significantly change over the course of 14 weeks, we discovered that expression of a4b1 distinctly declined over the observed course in almost all patients with CD, but not in those with UC (Fig.  2C ). This might be explained by peripheral contraction of a4b1-expressing cells in favor of compensatory enrichment in the intestinal lamina propria in CD, when a4b7-dependent homing is blocked. On the contrary, upregulation of CCR2 in patients with CD does not seem to result in counter-regulatory, increased CCR2-dependent homing in patients receiving vedolizumab. Consistently, stainings of cryosections from biopsies of patients with CD undergoing colonoscopy directly before initiation of therapy with vedolizumab or follow-up colonoscopy during the maintenance phase of vedolizumab treatment indicated that the number of a4b1-positive cells was increased in the latter group (Supplemental Digital Content 2C, http://links.lww.com/ IBD/B456). Moreover, we found that a significant portion of a4b7 + cells coexpresses a4b1 (Supplemental Digital Content 2D, http://links.lww.com/IBD/B456). As this was consistent with the idea that vedolizumab-induced blockade of the a4b7 homing pathway might be circumvented by the a4b1 pathway, we focused on a4b1 and its ligand VCAM-1 in further steps.
Preferential Ileal Homing of CD Teff Cells
Besides homing through alternative pathways, we also considered that regarding the clinical distribution of CD, it might be additionally relevant to study ileal homing with CD Teff cells. Accordingly, we determined ileal homing of Teff cells in vivo in our mouse model. First, we assessed the expression of VCAM-1, the receptor for a4b1 in the ileum of the DSS-treated mice used in our study by performing immunohistochemistry on ileal cryosections from DSS-treated and untreated mice. We found that while expression in noninflamed tissue was low, it was markedly upregulated in the ileum of DSS-treated mice (Fig. 3A) . Thus, although macroscopic signs of ileal inflammation are largely absent on DSS treatment, this finding added to earlier reports, fueling the notion that some features of inflammation extend beyond the colon to the ileum [16] [17] [18] and, more specifically, suggested that our model is valid for the investigation of a4b1-dependent ileal homing, as it served to induce the necessary ligand in the ileum. Moreover, after adoptive transfer of untreated Teff cells from patients with CD to the ileocolic artery of DSS-treated mice, intravital confocal microscopy demonstrated homed T cells in ileal villi (Fig. 3B) , similarly supporting the applicability of our model for the exploration of in vivo homing to the ileum.
Next, we compared colonic and ileal homing after adoptive transfer of untreated CD Teff cells. We observed high amounts of human CD Teff cells in the murine ileum by in vivo microscopy, although colonic numbers were markedly lower (Fig. 3C ). Quantification by flow cytometry of lamina propria mononuclear cells isolated from the mice confirmed this observation, because a significant difference was noted between ileal and colonic CD Teff cell infiltrates. This difference was more pronounced in patients with CD with small intestinal involvement (L1 and L3 phenotypes according to the Montreal classification) than in patients without ileal involvement (L2 phenotype) (Supplemental Digital Content 3, http://links.lww.com/IBD/B457).
To exclude that this observation was an effect related to our in vivo model, we performed similar experiments with untreated cells from healthy control donors. Here, colonic and ileal cell accumulation were not significantly different but tended towards higher colonic levels (Fig. 3D) . This suggested that the effects seen with CD Teff cells were specific for the disease.
This was consistent with the notion that unaffected colonic homing of CD Teff cells treated with vedolizumab in our humanized mouse model might be explained not only by alternative homing through a4b1 and VCAM-1, but also by a predominant role of ileal homing in CD.
Static and Dynamic Adhesion to VCAM-1 Is Blocked by Natalizumab
Hence, we decided to study adhesion of a4b1 to VCAM-1 more closely. VCAM-1-coated glass slides were incubated with Teff cells from patients with CD who had been treated with different concentrations of vedolizumab and natalizumab in vitro (Fig. 4A, C) . As expected, the anti-a4 antibody natalizumab dose-dependently reduced adherence of Teff cells to VCAM-1, whereas vedolizumab had a significant effect only at nonphysiologically relevant concentrations 19 matching with previous data that report some binding of a4b7 to VCAM-1 as well. 20, 21 However, these experiments only addressed static adhesion and might therefore not fully reflect the physiological situation, where adhesion happens under the dynamic flow conditions of the blood stream with shear stress. Thus, we refined our technique to investigate adhesion to VCAM-1 under flow by perfusing VCAM-1-coated ultra-thin glass capillaries with suspensions of CD Teff cells (Fig. 4B , Supplemental Digital Content 4, http:// links.lww.com/IBD/B458).
Although virtually no cells adhered to uncoated glass capillaries, many untreated cells bound to VCAM-1-coated counterparts. Fitting to the observations under static conditions, adhesion of natalizumab-treated cells was obviously and significantly reduced, whereas vedolizumab had no significant effect (Fig. 4C) .
Pan-a4 but Not a4b7 Inhibition Blocks Ileal Homing of CD Teff Cells In Vivo
Consequently, we compared the implications of a4b7 and a4 blockade for ileal homing in our humanized mouse model and transferred vedolizumab-and natalizumab-treated Teff cells from CD (Fig.  5A ). Quantitative analyses revealed that whereas vedolizumab only had a marginal effect that missed statistical significance, natalizumab significantly reduced ileal numbers of CD Teff cells (Fig. 5B) .
As natalizumab additionally blocks a4b1, this further supports the concept that this molecule might be essential in CD to explain our findings for a4b7.
Inhibition of a4b1 but Not a4b7 Blocks Ileal Homing of CD Teff Cells In Vivo
However, because natalizumab is a pan-a4 inhibitor, these experiments were not suitable to directly address the role of a4b1. Thus, we performed experiments using the specific a4b1 inhibitor BIO5192.
In vitro adhesion assays demonstrated that this inhibitor reduces adherence of CD Teff cells to VCAM-1 to a level comparable with natalizumab (Fig. 6A) . In our humanized mouse model, a4b1 inhibition with or without vedolizumab significantly reduced in vivo homing to the inflamed ileum, whereas vedolizumab alone again failed to induce a significant effect (Fig. 6B, C) .
Taken together, these findings suggested that blockade of a4b1 might be sufficient to impede homing of CD Teff cells to the inflamed ileum, whereas inhibition of a4b7-though preventing adhesion to MAdCAM-1-might be compensated by increased homing through a4b1.
DISCUSSION
Although the precise role of intestinal T lymphocyte trafficking in IBD is still incompletely understood, recent data from both basic and translational research and clinical advances have underscored the importance of this process in the framework of chronic intestinal inflammation. [22] [23] [24] [25] After the episode of natalizumab, which was effective in CD but led to serious safety concerns, 12, 26 this has finally been clinically implemented by the monoclonal anti-a4b7 integrin antibody vedolizumab.
The efficacy of vedolizumab in both UC and CD has been demonstrated in several trials, 9, 10 and no increased risk for infections of other organs has been reported so far, 27 thus supporting the concept of gut-specific inhibition of homing by this molecule. 7, 22 However, clinical observations also suggest that gut homing might be of differential relevance and might be differentially controlled in UC and CD as the main entities of IBD. In concrete terms, although it is beyond question that vedolizumab is effective in both diseases, several studies indicate that vedolizumab might be beneficial for a higher percentage of patients with UC than for those with CD or have a faster time to response in UC. 28 In the GEMINI 2 phase III induction trial, a significantly higher proportion of patients with CD receiving vedolizumab had a clinical remission compared with patients receiving placebo, but no significant effect was observed in the CDAI-100 response or in the change of CRP levels. In the maintenance study, higher rates of clinical remission and response compared with placebo were reported, yet, these differences only appeared very late in the 1-year course of therapy, and rates of durable clinical remission were similar. 10 In the GEMINI 3 trial, moreover, differences in clinical remission were only detectable at week 10 but not at week 6. 29 On the contrary, vedolizumab met all primary endpoints in the UC GEMINI 1 induction trial, i.e., clinical remission, clinical response, and mucosal healing. Moreover, it induced significantly higher rates of remission, response, mucosal healing, and steroid-free and durable remission in the maintenance phase. 9 Although some open-label studies reported similar efficacy in both diseases, 30, 31 later reports indicated higher percentages for remission, response, and mucosal healing in UC compared with CD, 32,33 matching with our own clinical experience. Moreover, 2 recent meta-analyses found higher RR values for remission and response endpoints in UC than in CD. 14, 34 To date, the reason for these differences is not clear. We have recently introduced a humanized mouse model taking advantage of DSS-treated immunodeficient mice to study vedolizumab effects on homing of T lymphocytes from patients with UC. 13, 35 Using this model, we now addressed colonic and ileal homing of CD effector T lymphocytes and reveal that redundant homing through a4b1 might be an explanation for the above mentioned observations. Although our first experiments confirmed that vedolizumab blocks a4b7-mediated adhesion to MAdCAM-1 in T lymphocytes from CD similarly to UC, we were astonished that we were not able to detect a significant effect in our humanized mouse model of homing to the inflamed colon. Compared with our previous data on UC, we only observed a modest decrease in colonic lymphocyte accumulation following treatment with vedolizumab that did not reach statistical significance. We had also shown that the peripheral Treg population increases within the first weeks of vedolizumab treatment in patients with UC resulting in a decreasing Teff/Treg ratio, which potentially leads to suppression of systemic inflammation. 13 Similar analyses in CD patients treated with vedolizumab at our department did not show any 4, 36 However, it underscores differences in a4b7-mediated homing and therapeutic a4b7 blockade between UC and CD.
We considered 3 potential approaches towards an explanation for our in vivo findings of only nonsignificant vedolizumab effects: First, lack of a4b7-dependent homing of CD Teff cells in our system. However, regarding the clear effect of vedolizumab on CD T lymphocytes in vitro, the previously observed effects of vedolizumab on UC T cell homing, the expression of murine MAdCAM-1 in DSS-treated immunodeficient mice, and the ability of human a4b7 to bind to murine MAdCAM-1, 13 it was very unlikely that vedolizumab would not inhibit interaction of a4b7 with MAdCAM-1 and thus a4b7-dependent homing in our humanized in vivo model. Second, compensatory homing through alternative receptors, i.e., a partly redundant role of a4b7 in CD. Consequently, we analyzed the expression of alternative homing markers on Teff lymphocytes and, in fact, we found a significant upregulation of a4b1 and CCR2 in the peripheral blood and the gut in CD but not in UC compared with controls. Sequential measurements of a4b1 on Teff cells from patients with CD treated with vedolizumab revealed a reduction of the peripheral expression in the course of treatment, whereas-reciprocally-immunohistochemistry of gut tissue suggested an intestinal increase. This was indeed compatible with a compensatory shift of a4b1 + Teff cells from the peripheral blood to the diseased intestine. A similar concept has earlier been established in a murine model of chronic ileitis, where single blockade of neither a4b7 nor MAdCAM-1 resulted in disease protection. However, the authors could show that the combination of MAdCAM-1 and L-Selectin inhibition reduced disease severity, and as a4b1 and a4b7 were frequently coexpressed, they proposed that interference with one of these pathways might result in alternative homing through the other one. 37 An earlier report from the same group pointed in a similar direction. Here, single blockade of the addressins ICAM-1, VCAM-1, or the integrin a4 had no effect on murine ileitis, whereas dual inhibition of ICAM-1 with VCAM-1 or a4 reduced colitis severity. 38 In this context, it is also interesting to mention that alicaforsen, an antisense inhibitor of ICAM-1 did not show efficacy in CD, which might also be explained by redundant homing pathways. 39 Third, an only minor role of colonic homing in CD compared with UC. Addressing this possibility, we compared ileal and colonic homing of CD Teff lymphocytes and found that more of these cells homed to the ileum than to the colon. Given the prevalent disease distribution, 3 this seems not very surprising and, thus, we decided to study a4b1-and a4b7-dependent homing of cells from patients with CD to the murine ileum.
In these experiments, we could demonstrate that-again -a4b7 inhibition through vedolizumab caused a nonsignificant minor decrease in homing, whereas blockade of a4 with natalizumab and thus a4b7 in combination with a4b1 resulted in a marked reduction of homing. This was consistent with compensatory a4b1-dependent homing in the presence of anti-a4b7 treatment. However, it did not answer the question of whether a4b7 might also work as an alternative pathway bypassing a4b1 blockade. We thus treated mice with an a4b1 inhibitor and compared the effects to vedolizumab. Both a4b1 inhibitor alone and in combination with vedolizumab resulted in a significant decrease of homed cells compared with no treatment or only vedolizumab treatment. This observation favors the idea that whereas a4b7 blockade can be circumvented by a4b1-dependent homing, a4b1 is essential for ileal homing of Teff cells in CD, and its blockade cannot be evaded by compensatory use of the a4b7 pathway (Fig. 7) .
It is not finally clear why this seems to be clinically relevant in CD but not in UC. Whereas one reason might be the higher expression of a4b1 in CD, another possibility is that a4b7 circumvention by a4b1 is not a specific feature of homing in CD but rather a feature of ileal compared with colonic homing. Another issue in this context might be time. As mentioned above, significant effects of vedolizumab in CD were more likely to be FIGURE 7 . Schematic model of a4b7-and a4b1-dependent homing and interference with vedolizumab in CD (left side) and UC (right side). In CD, blockade of a4b7 through vedolizumab is circumvented by ileal homing through a4b1, which is expressed in increased levels. In UC, vedolizumab-induced inhibition of a4b7 leads to significant reduction of colonic homing.
observed at later time points in clinical trials. 10, 29 Naturally, our model only examines short-term trafficking and is therefore not able to reveal long-term effects of the drugs tested. Thus, it is possible that vedolizumab exerts its effect in CD by constantly leading to slight reductions in homing that have to accumulate over time before active inflammation is measurably suppressed. Apart from this, and regarding our data, it seems essential to place effort in the identification of suitable biomarkers to predict the individual response to vedolizumab therapy like it was conceptually shown for adalimumab or etrolizumab. 24, 40 Taken together, our data show for the first time that human Teff cells may circumvent inhibition of one integrin by homing to the inflamed gut through another one in vivo and thereby evade targeted anti-integrin therapy. These findings emphasize the need for refinement of current and development of future therapies interfering with intestinal trafficking.
